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Many details of the molecular and cellular mechanisms involved in Mycobacterium bovis bacillus Calmette-Gu´ erin (BCG)
immunotherapy of bladder cancer have been discovered in the past decades. However, information on a potential role for
macrophage cytotoxicity as an eﬀector mechanism is limited. Macrophages play pivotal roles in the host innate immunity and
serve as a ﬁrst line of defense in mycobacterial infection. In addition to their function as professional antigen-presenting cells,
the tumoricidal activity of macrophages has also been studied with considerable interest. Studies have shown that activated
macrophages are potent in killing malignant cells of various tissue origins. This review summarizes the current understanding of
the BCG-induced macrophage cytotoxicity toward bladder cancer cells with an intention to inspire investigation on this important
but underdeveloped research ﬁeld.
1. RoleofMacrophagesinBCGImmunotherapy
of Bladder Cancer
Intravesical instillation of BCG is used for the treatment
of superﬁcial transitional cell carcinoma (TCC) of the
bladder to reduce recurrence and progression of this disease.
Since its ﬁrst therapeutic application in 1976 [1], major
eﬀorts have been directed to decipher the mechanisms
through which BCG mediates antibladder cancer immunity.
Although the exact mechanism of BCG action remains
elusive, an induction of localized cellular immune responses
reﬂecting activation of various types of immune cells has
been proposed [2, 3]. Potential eﬀector cells responsible
for tumor killing include MHC-restricted cytotoxic T cells
(CD8+ CTL) and CD4+ T cells [4, 5], MHC-nonrestricted
c e l l ss u c ha sn a t u r a lk i l l e r( N K )c e l l s[ 6–8], lymphokine-
activated killer (LAK) cells [8, 9] and BCG-activated killer
(BAK) cells [10–12], CD1-restricted CD8+ T cells [13],
γδ T cells [14–16], natural killer T (NKT) cells [15–17],
neutrophils [18, 19], and macrophages [20–22]. Several
lines of evidence suggest that macrophages actively mediate
antibladder cancer immunity induced by BCG. Following
BCG instillation, increased numbers of macrophages, along
with T cells, NK cells, dendritic cells (DC), and neutrophils,
were observed in bladder cancer inﬁltrates and the peritu-
moralbladderwall[2,3,23–26].Thevoidedurineofbladder
cancerpatientsafterBCGtreatmentalsocontainedincreased
numbers of macrophages and other types of immune cells
[27–29]. Moreover, a transient secretion of various cytokines
and chemokines in patients’ urine after intravesical BCG
treatment has been reported, including those predominantly
produced by macrophages such as TNF-α, IL-6, IL-10, IL-
12, and IL-18 [2, 3, 29–35]. Furthermore, both human
a n dm u r i n em a c r o p h a g e sh a v eb e e no b s e r v e dt op r o d u c e
TNF-α,I F N - γ, IL-6, IL-10, IL-12, and IL-18 in response
to BCG stimulation in vitro [36–39]. In addition to their
cytokine/chemokine production, both human and murine
macrophages can also act as cytotoxic eﬀector cells toward
bladdercancercellsuponactivationbyBCGinvitro[40–46].
It has been postulated that, in the case of intravesical BCG
treatment of bladder cancer, the bladder mucosa develops
BCG-mediated inﬂammatory responses, which involve the
initial binding of BCG to ﬁbronectin on the urothelium
[47], followed by internalization of BCG by urothelial cells,
and subsequent activation of various immune cells including
macrophages in the bladder wall [47, 48]. Once activated2 Clinical and Developmental Immunology
by BCG, macrophages gain eﬀector functions to act as
inﬂammatory, microbicidal, and tumoricidal cells in BCG-
induced anti-bladder cancer immune responses.
2. BCG-InducedMacrophage Cytotoxicity
The BCG induction of macrophage cytotoxicity can be de-
monstrated in vitro through a cytotoxicity assay in which
macrophages are preactivated with BCG and then coincu-
bated with radioisotope-labeled bladder cancer cells, foll-
owed by analysis of radioisotope release from target cells
in culture supernatants. Using this method, Pryor and asso-
ciates reported that BCG could enhance monocytes/mac-
rophages from human peripheral blood to kill bladder can-
cer UCRU-BL-17 cells [40]. Although na¨ ıve monocytes/
macrophages exhibited minimum cytotoxicity, the cyto-
toxic activity of the cells was signiﬁcantly enhanced upon
BCG stimulation. In addition, BCG appeared to be sup-
erior to IFN-α,I F N - γ, and IL-2 in enhancing monocyte/
macrophage-mediated cytotoxicity. However, the BCG-
activated monocytes/macrophages failed to show consistent
cytotoxicity toward bladder cancer 5637, T24, and J82 cells,
although all these cell lines including UCRU-BL-17 were
similarly susceptible to BCG direct killing [40]. Possible
explanations for this discrepancy might relate to diﬀerential
expression of the receptors of cytotoxic eﬀector molecules on
target cells or adhesion molecules on both eﬀector and target
cells. These possibilities wait to be investigated.
Yamada and associates reported that thioglycollate-
elicited peritoneal macrophages from C3H/HeN mice were
cytotoxictosyngeneicbladdercancerMBT-2cellsuponBCG
stimulation [41–43]. This BCG-induced macrophage cyto-
toxicity was correlated with the production of TNF-α,I F N -
γ, and IL-12 by macrophages. In addition, viable BCG was
observed to be superior to nonviable BCG for the induction
of macrophage cytotoxic activity and cytokine production
[42, 43]. Yamada and associates further observed that
C3H/HeN macrophages produced prostaglandin (PG) E2
along with other cytokines in response to BCG stimulation
[43]. PGE2 exhibited an inhibitory eﬀect on BCG-induced
C3H/HeNmacrophagecytotoxicitytowardMBT-2cells[43].
Inhibition of cyclooxygenase (COX)-1 and/or COX-2, the
enzymes responsible for the formation of prostanoids such
as PGE2 [49], during BCG stimulation could enhance the
macrophage cytotoxic activity and production of TNF-α and
IFN-γ [43]. These observations suggested that an inhibitor
of PG synthesis might be potentially useful for enhancing
BCG immunotherapy of bladder cancer. Subsequently, our
own studies demonstrated the ability of BCG to induce the
cytotoxic activity of C3H/HeN macrophages toward MBT-2
cells [44–46]. We were able to show that BCG was superior
to lipopolysaccharide (LPS) for the induction of macrophage
cytotoxicity [45, 46]. Our investigations further demon-
strated that endogenous T helper type (Th) 1 cytokines IFN-
γ, IL-12, and IL-18 as well as proinﬂammatory cytokine
TNF-α played an important role in BCG-induced C3H/HeN
macrophage cytotoxicity and that supplementation of BCG
with exogenous recombinant (r) IL-12 and rIL-18 could
enhance the macrophage cytotoxicity [45].
In addition to C3H/HeN macrophages, we have also
observed that BCG could induce cytotoxic activity of
macrophages from C57BL/6 mice toward syngeneic bladder
cancer MB49 cells [46]. Further, both BCG-activated C3H/
HeN macrophages and BCG-activated C57BL/6 macro-
phages were capable of killing allogeneic bladder cancer cells
reciprocally, although such killing was less potent than those
toward syngeneic bladder cancer cells [46]. Compared to
BCG-activated C3H/HeN macrophages, the cytotoxic activ-
ityofBCG-activatedC57BL/6macrophageswassubstantially
weak. Since both MBT-2 cells and MB49 cells showed
similar susceptibility to macrophage-derived cytotoxic eﬀec-
tor molecules such as TNF-α and nitric oxide (NO) [46],
Th2 cytokine(s) produced by BCG-activated macrophages
might be causative for the reduced cytotoxicity of C57BL/6
macrophages. To determine this, we conducted a study
in which macrophages of both genetic backgrounds were
assessed in parallel for their cytokine and NO production
[46]. We found that macrophage-derived IL-10 played an
inhibitoryroleinBCG-inducedmacrophagecytotoxicityand
was responsible for the BCG induction of reduced cytotoxic
activity of C57BL/6 macrophages [46]. However, diﬀerential
expression of IL-10 receptors on bladder cancer cells and/or
macrophages from the two diﬀerent genetic backgrounds
might also play a role in susceptibility of the tumor cells
to BCG-induced macrophage cytotoxicity. Thus, although
both MBT-2 cell and MB49 cell-derived bladder cancers in
syngeneicmice,twowidelyusedbladdercancermodels,have
been demonstrated to be similarly responsive to intravesical
BCG treatment [50, 51], the detailed mechanisms through
which BCG induces antitumor immunity in these two
distinctive genetic backgrounds of mice are apparently not
identical.
3.Mechanismof BCG-Induced
Macrophage Cytotoxicity
Multiple eﬀector mechanisms are involved in the killing of
bladder cancer cells by BCG-induced macrophage cytotox-
icity. Both direct eﬀector-target cell contact and release of
soluble cytotoxic factors (such as TNF-α,IFN-γ and NO) are
required for eﬀective killing of bladder cancer cells by BCG-
activated macrophages [45]. The eﬀector-target cell contact
w a so b s e r v e dt oc o n t r i b u t et oa p p r o x i m a t e l y5 0 %o ft h e
total killing of MBT-2 cells by BCG-activated C3H/HeN
macrophages [45]. However, knowledge about the mech-
anism of cell-cell contact mediated killing is scarce. BCG
infection may result in up-regulated expression of adhesion
molecules such as lymphocyte function-associated antigen-1
(LFA-1) or apoptosis-inducing molecules such as Fas ligand
and TRAIL on macrophages [52–54]. Acquirement of these
surface molecules could direct macrophages to bind to and
kill bladder cancer cells. This assumption of phenotypical
changes of macrophages has been a subject of study that
should yield valuable insights into the mechanism of BCG
action.
Soluble factors released from macrophages were also
found to account for approximately 50% of the total killing
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[45]. Soluble factors released from BCG-activated human
monocytes/macrophages contributed to the total killing
of UCRU-BL-17 cells even higher than eﬀector-target cell
contact [40]. Production of TNF-α,I F N - γ,a n dN Ob y
macrophages in response to BCG stimulation has been
observed in vitro [36–39, 41–46, 55, 56]. These eﬀector
factors are known to be cytotoxic to bladder cancer cells
[45, 46, 57–59] and kill target cells through the apoptotic
and/or necrotic pathways [60–62]. In addition to the killing
of bladder cancer cells, both TNF-α and IFN-γ are also
knowntoworkthroughautocrineformacrophageactivation
and NO production [38, 56, 63–65]. NO is a reactive nitro-
gen/oxygen intermediate with strong cytotoxicity toward
malignant cells. It has been demonstrated to kill both human
and murine bladder cancer cells in vitro [46, 66–68]. Thus,
production of TNF-α,I F N - γ, and NO renders macrophages
activation and cytotoxic activity. Indeed, high BCG-induced
macrophage cytotoxicity has been observed to correlate with
high production of these cytotoxic eﬀector molecules [45,
46].
4. Role of Th1 andTh2 Cytokines in
BCG-InducedMacrophage Cytotoxicity
Macrophagesproduceinﬂammatorycytokines,suchasTNF-
α,I F N - γ, IL-6, IL-10, IL-12, and IL-18, in response to
BCG stimulation [36–39, 41–46]. These cytokines act in a
reciprocal fashion and are tightly controlled for a proper
induction of Th1/Th2 immune responses. Acquirement
of a Th1 immune response is essential to eﬀective BCG
immunotherapy of bladder cancer [2, 3, 32–34, 69]. In
addition,Th1cytokinesarealsofoundtobevitalfortheBCG
induction of macrophage tumoricidal activity.
4.1. Role of Th1 Cytokines. It has been observed that Th1
cytokines IFN-γ, IL-12, and IL-18 play a positive role
in BCG-induced macrophage cytotoxicity toward bladder
cancer cells [43, 45]. Proinﬂammatory cytokine TNF-
α has also been observed to be critical in the BCG-
induced macrophage cytotoxicity [43, 45]. Blockage of these
endogenous cytokines by neutralizing antibodies signiﬁ-
cantly reduced BCG-induced C3H/HeN macrophage cyto-
toxicity toward MBT-2 cells [43,45]. Among thesecytokines,
neutralization of TNF-α led to the most severe inhibition on
macrophage cytotoxicity [45]. To support this role of Th1
cytokines,ithasbeenobservedthatsupplementationofBCG
w i t he x o g e n o u sr I L - 1 2o rr I L - 1 8r e s u l t e di na ni n c r e a s ei n
the induction of macrophage cytotoxicity [45]. Moreover,
C3H/HeN macrophages treated with rBCG expressing IL-
18 exhibited increased killing of MBT-2 cells, along with
increased production of TNF-α and IFN-γ [44, 45]. In
addition, C3H/HeN macrophages developed enhanced cyto-
toxicity after stimulation with BCG plus rIL-2 or with
rBCG expressing IL-2 [41, 45]. These observations suggest
that Th1 cytokines play a pivotal role in BCG-induced
macrophage cytotoxicity and that combination of BCG
with Th1 cytokines may enhance the eﬀect of BCG in the
treatment of bladder cancer patients.
4.2. Role of Th2 Cytokines. IL-10, one of the major Th2
cytokines produced by macrophages, is inhibitory to the
BCG induction of macrophage cytotoxicity. High IL-10
production was observed to correlate with low killing of
MB49 cells and reduced production of TNF-α,I L - 6 ,a n d
NObyBCG-activatedC57BL/6macrophage[46].Tosupport
this inhibitory role of IL-10, neutralizing endogenous IL-10
during BCG stimulation resulted in increased BCG-induced
C57BL/6 macrophage cytotoxicity toward MB49 cells, along
with increased production of TNF-α and NO [46]. Since
supplementation of exogenous rTNF-α failed to enhance
the BCG-induced macrophage cytotoxicity, IL-10 appeared
to play a predominant role in controlling the induction
of C57BL/6 macrophage cytotoxicity by BCG [46]. Further
evidence supporting the inhibitory role of IL-10 includes the
studies that showed high BCG-induced cytotoxicity toward
MB49 cells by macrophages from genetically modiﬁed
C57BL/6 mice lacking IL-10 (IL-10−/−)a n dr e d u c e dB C G -
induced cytotoxicity toward MBT-2 cells as well as MB49
cells by C3H/HeN macrophages pretreated with exogenous
rIL-10 [46]. In addition, studies have also shown that IL-10
could inhibit macrophage release of cytokines (e.g., TNF-
α) and reactive nitrogen/oxygen intermediates (e.g., NO)
[70–73]. Thus, IL-10 is inhibitory to the inﬂammatory,
microbicidal and tumoricidal activities of macrophages.
These observations suggest that blockage of IL-10 may
potentially enhance the eﬀect of BCG in the treatment of
bladder cancer patients, particularly for BCG nonresponders
who often develop high IL-10 levels during BCG treatment
[32–34].
The role of IL-6 in BCG-induced macrophage cyto-
toxicity remains elusive. Production of IL-6, along with
TNF-α,I F N - γ,a n dN O ,w a so b s e r v e dt oc o r r e l a t ew i t h
the BCG induction of cytotoxic activity of both C3H/HeN
macrophages and C57BL/6 macrophages [45, 46]. IL-6 is
known to be involved in macrophage maturation [74],
and thus may contribute to BCG-induced macrophage
cytotxicity through its inﬂuence on macrophage release of
cytotoxic eﬀector molecules and/or expression of surface
adhesion and apoptosis-inducing molecules. In addition, the
fates of supplementation of exogenous rIL-6 or blockage
of endogenous IL-6 on BCG induction of macrophage
cytotoxicity are unknown.
5. Conclusion and FutureView
In vitro studies have demonstrated the ability of BCG to
induce macrophage cytotoxicity toward bladder cancer cells
in both human and murine. This macrophage-mediated
killing of bladder cancer cells depends on both direct
eﬀector-target cell contact and release of soluble cytotoxic
factors, such as TNF-α,IFN-γ, and NO, from macrophages.
Th1 cytokines IFN-γ, IL-12, and IL-18 as well as proinﬂam-
matory cytokine TNF-α play positive roles in BCG-induced
macrophage cytotoxicity whereas Th2 cytokine IL-10 plays
a negative role in BCG-induced macrophage cytotoxicity.
Supplementation of exogenous Th1 cytokines such as rIL-12
and rIL-18 or inhibition of endogenous Th2 cytokine IL-10
enhances BCG-induced macrophage cytotoxicity. However,4 Clinical and Developmental Immunology
despite these ﬁndings, there are some unsolved issues with
respect to the BCG-induced macrophage cytotoxicity: (1)
how potent is the cytotoxic activity of macrophages relative
to T cells, NK cells, LAK cells, BAK cells, and NKT cells in
killing bladder cancer cells?, (2) what are the phenotypical
changesof macrophagesin response to BCG stimulation that
facilitate macrophages to contact bladder cancer cells?, (3)
why do BCG-activated macrophages exhibit no cytotoxicity
toward some human bladder cancer cell lines?, and (4) what
is the actual role of IL-6 in BCG-induced macrophage cyto-
toxicity toward bladder cancer cells? In addition, although
BCG-induced macrophage cytotoxicity has been demon-
strated in vitro, there is a lack of evidence supporting the role
of macrophage cytotoxicity in BCG-mediated eradication of
bladder cancer in vivo. As technology develops, we anticipate
that these issues will be approached and answered. A better
understanding of the role of macrophages in BCG mediated
immune responses will no doubt add to our proper design
and application of BCG immunotherapy for bladder cancer.
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